The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
 
Anup Kasi
Consulting or Advisory Role - Ipsen
Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
 
Milind A. Phadnis
No Relationships to Disclose
 
Raed Moh'd Taiseer Al-Rajabi
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Seagen
Consulting or Advisory Role - AstraZeneca; Bayer
Speakers' Bureau - Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lexicon (Inst); Lilly (Inst); Merck (Inst); Sillajen (Inst)
 
Joaquina Celebre Baranda
No Relationships to Disclose
 
Haoran Li
No Relationships to Disclose
 
Erin Carroll
No Relationships to Disclose
 
Cathey Belcher
No Relationships to Disclose
 
Shannon Bradbury
No Relationships to Disclose
 
Zachary Collins
No Relationships to Disclose
 
Weijing Sun
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Macrogenics
Research Funding - AstraZeneca (Inst); Merck (Inst); Novella Clinical (Inst)